Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

Shiro Saito, Kazuto Ito, Atsunori Yorozu, Manabu Aoki, Hirofumi Koga, Takefumi Satoh, Toshio Ohashi, Naoyuki Shigematsu, Shinichiro Maruo, Takashi Kikuchi, Shinsuke Kojima, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40 % of all cases treated around the country. During the first 2 years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89 years (median 69 years) and their risk classifications were 1,037 (44.3 %) at low risk, 1,126 (48.1 %) at intermediate risk, and 134 (5.7 %) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6 % were treated with PI without external beam radiation therapy and 49.3 % received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40 % of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up.

Original languageEnglish
Pages (from-to)375-385
Number of pages11
JournalInternational Journal of Clinical Oncology
Volume20
Issue number2
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Iodine
Prostatic Neoplasms
Seeds
Outcome Assessment (Health Care)
Quality of Life
Disease-Free Survival
Neoadjuvant Therapy
Survival
Brachytherapy
Prostate
Japan
Cohort Studies
Radiotherapy
Hormones
Prospective Studies
Safety
Incidence

Keywords

  • Brachytherapy
  • Iodine-125
  • Multi-institutional prospective cohort study
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). / Saito, Shiro; Ito, Kazuto; Yorozu, Atsunori; Aoki, Manabu; Koga, Hirofumi; Satoh, Takefumi; Ohashi, Toshio; Shigematsu, Naoyuki; Maruo, Shinichiro; Kikuchi, Takashi; Kojima, Shinsuke; Dokiya, Takushi; Fukushima, Masanori; Yamanaka, Hidetoshi.

In: International Journal of Clinical Oncology, Vol. 20, No. 2, 01.04.2015, p. 375-385.

Research output: Contribution to journalArticle

Saito, S, Ito, K, Yorozu, A, Aoki, M, Koga, H, Satoh, T, Ohashi, T, Shigematsu, N, Maruo, S, Kikuchi, T, Kojima, S, Dokiya, T, Fukushima, M & Yamanaka, H 2015, 'Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)', International Journal of Clinical Oncology, vol. 20, no. 2, pp. 375-385. https://doi.org/10.1007/s10147-014-0704-4
Saito, Shiro ; Ito, Kazuto ; Yorozu, Atsunori ; Aoki, Manabu ; Koga, Hirofumi ; Satoh, Takefumi ; Ohashi, Toshio ; Shigematsu, Naoyuki ; Maruo, Shinichiro ; Kikuchi, Takashi ; Kojima, Shinsuke ; Dokiya, Takushi ; Fukushima, Masanori ; Yamanaka, Hidetoshi. / Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). In: International Journal of Clinical Oncology. 2015 ; Vol. 20, No. 2. pp. 375-385.
@article{03058a2076984ef49a35882b0675af40,
title = "Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)",
abstract = "Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40 {\%} of all cases treated around the country. During the first 2 years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89 years (median 69 years) and their risk classifications were 1,037 (44.3 {\%}) at low risk, 1,126 (48.1 {\%}) at intermediate risk, and 134 (5.7 {\%}) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6 {\%} were treated with PI without external beam radiation therapy and 49.3 {\%} received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40 {\%} of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up.",
keywords = "Brachytherapy, Iodine-125, Multi-institutional prospective cohort study, Prostate cancer",
author = "Shiro Saito and Kazuto Ito and Atsunori Yorozu and Manabu Aoki and Hirofumi Koga and Takefumi Satoh and Toshio Ohashi and Naoyuki Shigematsu and Shinichiro Maruo and Takashi Kikuchi and Shinsuke Kojima and Takushi Dokiya and Masanori Fukushima and Hidetoshi Yamanaka",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10147-014-0704-4",
language = "English",
volume = "20",
pages = "375--385",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

AU - Saito, Shiro

AU - Ito, Kazuto

AU - Yorozu, Atsunori

AU - Aoki, Manabu

AU - Koga, Hirofumi

AU - Satoh, Takefumi

AU - Ohashi, Toshio

AU - Shigematsu, Naoyuki

AU - Maruo, Shinichiro

AU - Kikuchi, Takashi

AU - Kojima, Shinsuke

AU - Dokiya, Takushi

AU - Fukushima, Masanori

AU - Yamanaka, Hidetoshi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40 % of all cases treated around the country. During the first 2 years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89 years (median 69 years) and their risk classifications were 1,037 (44.3 %) at low risk, 1,126 (48.1 %) at intermediate risk, and 134 (5.7 %) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6 % were treated with PI without external beam radiation therapy and 49.3 % received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40 % of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up.

AB - Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40 % of all cases treated around the country. During the first 2 years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89 years (median 69 years) and their risk classifications were 1,037 (44.3 %) at low risk, 1,126 (48.1 %) at intermediate risk, and 134 (5.7 %) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6 % were treated with PI without external beam radiation therapy and 49.3 % received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40 % of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up.

KW - Brachytherapy

KW - Iodine-125

KW - Multi-institutional prospective cohort study

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84939449240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939449240&partnerID=8YFLogxK

U2 - 10.1007/s10147-014-0704-4

DO - 10.1007/s10147-014-0704-4

M3 - Article

VL - 20

SP - 375

EP - 385

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -